Treating Metastatic NSCLC: Choosing the Best Treatment for Optimal Outcomes

A 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.

Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.

Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy.

An expert discussion surrounding experience with managing weight gain and gastrointestinal adverse events associated with lorlatinib, addressing quality of life, symptom mitigation strategies, and maintaining treatment efficacy.